In celebration of November’s Native American Heritage Month and Stomach Cancer Awareness Month observances, the John Wayne Cancer Foundation is funding research that will allow doctors to assess barriers to treatment of H. pylori and disseminate findings to community health partners to reduce the occurrence of stomach cancer.
Alligator Bioscience on May 26 announced that the European Commission granted orphan drug designation to HLX22, an anti-HER2 monoclonal antibody, for the treatment of gastric cancer. HLX22 is being developed by Shanghai Henlius Biotech, Inc. under a sublicense from AbClon, Inc., which had previously licensed the antibody from Alligator.
